siRNA therapy decreases triglycerides in patients along with uncommon ailment

.STUDY FEATURE.19 September 2024.

Plozasiran decreased triglyceride levels by 80% and reduced the risk of pancreatitis in patients with chronic chylomicronemia, with or even without a hereditary medical diagnosis.